ADAG News and Press, Adagene Inc. From 06/29/22

Adagene ( NASDAQ: ADAG ) on Wednesday authorized a share buyback of up to $10M of its U.S.-listed shares. The micro-cap company's stock surged ~30% to $2.72 in aftermarket trading. ADAG said it expects to use its existing funds to fund repurchases made under the sh...

SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that its board of directors has authorized a share repurchase program...

The following slide deck was published by Adagene Inc. in conjunction with this event. For further details see: Adagene (ADAG) Investor Presentation - Slideshow

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN ...

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in th...

- Poster presentations showcase SAFEbody ® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates in 2022, including masked anti-CD137 antibody with Fc engineering and masked ant...

Adagene ADR press release (NASDAQ:ADAG): FY GAAP EPS of -$1.46. Revenue of $10.2M (+1357.1% Y/Y). For further details see: Adagene ADR GAAP EPS of -$1.46, revenue of $10.2M

- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater efficacy through higher and more frequent dosing - - Advanced three wholly-owned cli...

Adagene (NASDAQ:ADAG) said it received FDA clearance to proceed with a phase 1b/2 trial of ADG126, in combination with the Merck's (NYSE:MRK) Keytruda (pembrolizumab) in solid tumors. The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumor...